SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and statins as a potential therapeutic treatment approach for chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC).
In a randomized, placebo controlled trial led by co-Investigator Adam Miller, MD, CEO, Medical Director, ARISE, a combination of maraviroc, a CCR5 antagonist, and a commonly administered statin, atorvastatin, will be evaluated for its efficacy in alleviating PASC symptoms.
In the trial, under an Enriched Enrollment Randomized Withdrawal (EERW) design, patients who experience symptomatic improvement with maraviroc and atorvastatin in an open label phase will enter a second phase and be randomized to continue active treatment or placebo.
The study aims to support clinical approaches developed by IncellDx’s Chronic COVID Treatment Center, which has enrolled more than 12,000 patients and published multiple articles on the application of precision medicine and biomarkers to determine the underlying pathways involved in PASC.
“At CCTC, we provide consultation to physicians across the country who are treating patients with chronic COVID,” said internist and physician Eric Osgood MD, physician, CCTC. “We are excited to partner with Dr. Miller to further evaluate the clinical observation that a biomarker-driven, precision medicine approach can result in improvement of long COVID symptoms as well as resolution of abnormal cytokine profiles that may be the underlying cause of this condition. In continuing to advance new research into diagnostic criteria and clinical approaches to treatment, we aim to provide lasting symptom alleviation in patients with PASC.”
“Based on outcomes we observe in long COVID patients being treated under the CCTC program protocol, we believe this condition can be objectively assessed and that addressing immune disruption from PASC may be central to its treatment,” said Dr. Miller. “Through this study, we aim to assess whether reducing the activity of CCR5 in the body with the use of CCR5 antagonists can play an important role in treatment of long COVID. We’ll also be evaluating the potential for the IncellDx Long Hauler Index, or LHI, to provide important diagnostic information about this condition that can inform treatment. We’re very excited about the potential of this study to validate clinical application of IncellDx’s LHI and a novel combination therapeutic approach leveraging already commonly used medicines.”
IncellDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company’s innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company launched the Chronic COVID Treatment Center to apply precision medicine approaches to evaluate, characterize and more effectively address chronic COVID.
About the Long Hauler Index
The Long Hauler Index or LHI was developed and patented by IncellDx to provide an objective method of identifying patients suffering from long COVID or PASC. The LHI assesses cytokines and chemokines believed to cytokine storm conditions and chronic COVID patients (often referred to as COVID “long haulers”).